Another MEK inhibitor, trametinib, was tested in a phase II trial in Japan in CCA patients, demonstrating SD in 65% of patients and progressive disease (PD) in 35%, with mPFS of 10.6 weeks and ~20% 1-year OS (Table 3) [80]. This evidence concerns the gene MAP2K7 and cholangiocarcinoma.